Encinitas, California-- (Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an ...

Salt Lake City, Utah--(Newsfile Corp. - November 18, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced today it has entered into warrant inducement offer letters ...

According to an SEC filing, TOI will pay Kiora an up-front payment of $16 million, and Kiora is eligible to receive milestone payments totaling up to approximately $285 million, upon and subject to ...

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in ...

Please provide your email address to receive an email when new articles are posted on . Théa Open Innovation will receive development and commercialization rights to KIO-301. KIO-301 demonstrated ...

Encinitas, California--(Newsfile Corp. - April 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (the "Company"), today announced that it has closed on a private placement providing up to $24 ...

Salt Lake City, Utah--(Newsfile Corp. - June 27, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") received approval to initiate a first-in-human clinical trial for KIO-301 ...

Salt Lake City, Utah--(Newsfile Corp. - December 15, 2021) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced the appointment of David Hollander, MD, MBA, to its Board ...

Encinitas, California--(Newsfile Corp. - May 9, 2025) - Kiora Pharmaceuticals, Inc. (KPRX) (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided ...

Please provide your email address to receive an email when new articles are posted on . Koira Pharmaceuticals, in a new partnership with the Choroideremia Research Foundation, plans to accelerate its ...